Примери за използване на Chromosome positive на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Glivec is used when the patients are‘Philadelphia chromosome positive'(Ph+).
Philadelphia chromosome positive acute lymphoblastic leukaemia(Ph-positive ALL).
Imatinib Accord is used when the patients are‘Philadelphia chromosome positive'(Ph+).
Newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia(CML) in the chronic phase.
Chronic myeloid leukaemia(CML)in the‘chronic' phase in newly diagnosed patients who are‘Philadelphia chromosome positive'(Ph+).
Tasigna is used to treat a type of leukaemia called Philadelphia chromosome positive chronic myeloid leukaemia(Ph-positive CML).
Philadelphia chromosome positive CML patients in chronic phase who have achieved a sustained deep molecular response(MR 4.5) on Tasigna following prior imatinib therapy.
Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia(Ph+ ALL) integrated with chemotherapy.
Philadelphia chromosome positive CML patients in chronic phase who have been treated with Tasigna as first-line therapy and who achieved a sustained deep molecular response(MR4.5).
This medicine is used to treat chronic myeloid leukaemia(CML) and Philadelphia chromosome positive(Ph+) acute lymphoblastic leukaemia(ALL) in adolescents and children from at least one year of age.
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients.
Chronic phase andaccelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
The European Medicines Agency has deferred the obligation to submit the results of studies with Tasigna in paediatric patients from birth to less than 18 years in the treatment of Philadelphia chromosome positive chronic myeloid leukaemia(see section 4.2 for information on paediatric use).
SPRYCEL is also a treatment for adults with Philadelphia chromosome positive(Ph+) acute lymphoblastic leukaemia(ALL), and lymphoid blast CML who are not benefiting from prior therapies.
There is no experience in paediatric patients below 2 years of age orin paediatric patients with Philadelphia chromosome positive CML in accelerated phase or blast crisis.
It is used when the patient is‘ Philadelphia chromosome positive'(Ph+), which means that some of the patient' s genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome. .
Tasigna is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia(CML) in the chronic phase.
Philadelphia chromosome positive acute lymphoblastic leukaemia(Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
A large, international, open-label, non-controlled phase II study was conducted in patients with Philadelphia chromosome positive(Ph+) CML in the blast crisis phase of the disease.
SPRYCEL is also used to treat Philadelphia chromosome positive(Ph+) acute lymphoblastic leukaemia(ALL) in adults, adolescents and children at least 1 year of age, and lymphoid blast CML in adults who are not benefiting from prior therapies.
The safety of nilotinib in paediatric patients(from 2 to< 18 years of age)with Philadelphia chromosome positive CML in chronic phase(n=69) has been investigated in two studies(see section 5.1).
Clinical studies in newly diagnosed CML in chronic phase An open-label, multicentre, randomised Phase III study was conducted to determine the efficacy of nilotinib versus imatinib in 846 adult patients with cytogenetically confirmed newly diagnosed Philadelphia chromosome positive CML in the chronic phase.
Tekinex was expected to be used to treat adults with‘Philadelphia chromosome positive'(Ph+) chronic myeloid leukaemia(CML, a cancer of a type of white blood cells called granulocytes).
Efficacy data in patients with CML in blast crisis are not available,- paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
SPRYCEL is also indicated for the treatment of adults with Philadelphia chromosome positive(Ph+) acute lymphoblastic leukaemia(ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
The Committee decided that Tasigna' s benefits are greater than its risks for the treatment of adults with chronic phase andaccelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Tasigna is indicated for the treatment of:- adult andpaediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia(CML) in the chronic phase,- paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.
Tasigna is indicated for the treatment of adultswith chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia(CML) with resistance or intolerance to prior therapy including imatinib.
The safety and efficacy of Tasigna in paediatric patients with Philadelphia chromosome positive CML in chronic phase from 2 to less than 18 years of age have been established(see sections 4.8, 5.1 and 5.2).
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive(Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha(IFN) therapy.